Simulations Plus Announces Release of New Toxicity Prediction for ADMET Predictor™
hERG Potassium Channel Blocking Affinity Models Important Cardiac Toxicity
Pharmacokinetic/Pharmacodynamic Model for the Safety of Tigecycline in Patients with Complicated Skin and Skin-Structure Infections
Tigecycline is a first-in-class glycylcycline for the treatment of serious bacterial infections. Reported adverse events from clinical trials include nausea and vomiting. Exposure-response relationships and…
Challenges in the transition to model-based development
Practitioners of the art and science of pharmacometrics are well aware of the considerable effort required to successfully complete modeling and simulation activities...
An evaluation of the utility of physiologically based models of pharmacokinetics in early drug discovery
Generic physiologically-based models of pharmacokinetics were evaluated for early drug discovery.
Simulations Plus Expands Field Sales Force
Product Manager to Become Full-time Field Representative
Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem
A doripenem population pharmacokinetic model and Monte Carlo simulations were utilized for dose regimen decision support for future clinical development.
Simulations Plus Acquires Assets of Sage Informatics LLC
New Product Line and Key Employee Expand Software Offerings and Science Staff
Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus
Varicella-zoster virus (VZV) is an alphaherpesvirus that causes varicella and herpes zoster. In these experiments, cDNA corresponding to 69 VZV open reading frames was...
Antimicrobial safety: focus on fluoroquinolones
Infrequent toxicities associated with certain drugs and drug classes have recently gained much attention from different health-care perspectives.
Simulations Plus Subsidiary, Words+, Inc., Terminates Royalty and Support Agreement with Sam Communications, LLC
Termination by Mutual Agreement to Result in Reduced Expenses
Simulations Plus Announces Release of ADMET Modeler™ 1.0 and Upgrade of ADMET Predictor™
Name change, new features, compatibility with ADMET Predictor™
Development Of A Pharmacokinetic (Pk) Model And Assessment Of Patient (Pt) Covariate Effects On Dose-Dependent Pk Following Different Dosing Schedules In Two Phase I Trials Of Ap23573 (Ap), An Mtor Inhibitor
AP23573 is a novel non-prodrug rapamycin analog that potently inhibits mTOR (through bivalent binding to FKBP and mTOR), a downstream effector of PI3K/Akt and nutrient-sensing pathways. A PK model was…
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi
Salmonella enterica serotype Typhi and nontyphoidal Salmonella remain major causes of morbidity and mortality worldwide.
Pharmacodynamic Characterization of NVP-LMB415 against Haemophilus Influenzae in an In Vitro Hollow-Fiber System
NVP-LBM415 is a peptide deformylase inhibitor with in vitro activity against those pathogens commonly associated with community-acquired respiratory tract infections. The purpose of these studies was to…
Exposure-Response Analysis Of The Efficacy Of Tigecycline In Patients With Complicated Skin And Skin-Structure Infections
Tigecycline, the first glycylcycline to reach clinical trials, is in development for the treatment of patients with serious infections, including complicated skin and skin-structure infections (cSSSI).
Pharmacokinetic/Pharmacodynamic Model For The Tolerability Of Tigecycline In Healthy Volunteers
Tigecycline, a first-in-class glycylcycline, is an antimicrobial agent with demonstrated in vitro activity against susceptible and multiple-drug resistant gram-positive and gram-negative bacteria.